Carbamazepine

An inhibitor of voltage-gated sodium channels

Carbamazepine is an inhibitor of sodium channels.1 It preferentially inhibits inactivated voltage-gated sodium channel Nav1.7 and Nav1.3 (IC50s = 406 and 900 µM, respectively) over resting (closed) Nav1.7 and Nav1.3 channels in whole-cell patch-clamp assays using HEK293 cells (IC50s = 1,584 and 2,464 µM, respectively). Carbamazepine (100 µM) inhibits sodium currents in a rat sciatic nerve patch-clamp assay ex vivo.2 It reduces levels of the endogenous catecholamine dopamine in the striatum and hippocampus, as well as the levels of the dopamine precursor L-DOPA (Item No. 13248) in the striatum, in rats when administered at a dose of 100 mg/kg.3 Dietary administration of carbamazepine (0.5% w/w) reduces amphetamine-induced hyperactivity in mice.4 It decreases immobility time in the forced swim test in mice when administered in the diet at 0.75% w/w. Formulations containing carbamazepine have been used in the treatment of seizures, trigeminal neuralgia, and bipolar disorder.

236.3

≥98%

CBZ|NSC 169864

NC(N1C2=C(C=CC=C2)C=CC3=C1C=CC=C3)=O

C15H12N2O

298-46-4

≥ 4 years

DMF: 25 mg/ml DMSO: 25 mg/ml DMSO:PBS(pH7.2) (1:1): 0.5 mg/ml Ethanol: 3 mg/ml